Physician profile
Ruth Karron
NPI 1154378339
$35,164.69
in general payments reported to CMS, 2019-2025
8 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,275 · 2021: $4,454 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,425 · Travel and Lodging: $935 · Food and Beverage: $88.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,425.00 |
| Travel and Lodging | $934.68 |
| Food and Beverage | $88.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $10,384.68 | 2025 | |
| Sanofi Pasteur INC. | $8,603.37 | 2019 | |
| Merck Sharp & Dohme LLC | $6,848.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $6,382.34 | 2019-2021 | |
| Modernatx, INC. | $1,800.00 | 2021 | |
| Pfizer INC. | $1,082.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $63.02 | 2025 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Karron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.